The report provides extensive insights into over 180 companies and 200 drugs in the PD-1 and PD-L1 inhibitors market. This comprehensive resource focuses on treatment assessments by product type, ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...

GSK plc with its development partner iTeos Therapeutics, Inc., has announced that it is ending the development programme for ...

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were trading at $30.25, down $5.60, or 15%, on word of the delay of data from the phase III X-tole2 trial with azetukalner in focal onset seizures ...

Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...